Alfred Okeke, MD
Endocrinology, Diabetes & Metabolism · Goldsboro, NCNPI 1093753436
Payments from drug & device makers
Across 408 payments — averaging $543.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$138K
- AstraZeneca$43K
- Bayer$27K
- Mannkind Corporation$5K
- Johnson & Johnson$2K
- Medtronic$2K
- plus $3K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 155 | $138,406 |
| AstraZeneca(2 entities) | 62 | $43,223 |
| Bayer | 36 | $27,299 |
| Mannkind Corporation | 17 | $5,079 |
| Johnson & Johnson | 9 | $2,382 |
| Medtronic(2 entities) | 18 | $2,065 |
| Sanofi-aventis U.S. LLC | 8 | $465 |
| Lilly USA, LLC | 15 | $266 |
| Zealand Pharma US, Inc. | 3 | $264 |
| Sequel Med Tech, LLC | 2 | $234 |
| Cequr Corporation | 2 | $210 |
| Lundbeck LLC | 11 | $201 |
| Aucta Pharmaceuticals, Inc. | 12 | $166 |
| Corcept Therapeutics | 7 | $138 |
| Neurocrine Biosciences, Inc. | 7 | $123 |
| Neurelis, Inc. | 6 | $116 |
| BETA Bionics, Inc. | 2 | $89 |
| Recordati_rare_diseases_inc. | 4 | $81 |
| Shire North American Group Inc | 1 | $63 |
| Boehringer Ingelheim | 3 | $56 |
| UCB, Inc. | 2 | $55 |
| Radius Health, Inc. | 1 | $50 |
| Merck | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Amgen | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Averitas Pharma Inc. | 1 | $32 |
| AbbVie | 2 | $32 |
| GSK | 2 | $30 |
| Verona Pharma, Inc. | 1 | $29 |
| TG Therapeutics, Inc. | 1 | $27 |
| Inogen, Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Insulet Corporation | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$221,549 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Goldsboro
- Kathryn LucasMorehead City$37.9M
- Mark WarrenGreenville$5M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
- Wendy LaneAsheville$1.9M
- Anthony BarberHickory$1.4M
- Klara KleinChapel Hill$1.3M
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.